Spots Global Cancer Trial Database for copanlisib
Every month we try and update this database with for copanlisib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | NCT04253262 | Metastatic Cast... | Rucaparib Copanlisib | 18 Years - | Brown University | |
| Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT03586661 | Deleterious BRC... Deleterious BRC... Endometrial Ade... High Grade Ovar... Platinum-Resist... Primary Periton... Progressive Dis... Recurrent Endom... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Copanlisib Niraparib | 18 Years - | M.D. Anderson Cancer Center | |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | NCT02728258 | Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri... | Copanlisib Laboratory Biom... | 18 Years - | NRG Oncology | |
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | NCT04431635 | Indolent Lympho... | Copanlisib Nivolumab Rituximab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | NCT04433182 | Diffuse Large B... | Copanlisib | 18 Years - | Fondazione Italiana Linfomi - ETS | |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | NCT03735628 | Non-small Cell ... Head and Neck S... Hepatocellular ... | Copanlisib Nivolumab | 18 Years - | Bayer | |
| Copanlisib in Association With Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas Harboring a PI3KCA Mutation/Amplification and/or a PTEN Loss | NCT02822482 | Carcinoma, Squa... | Copanlisib Cetuximab | 18 Years - | UNICANCER | |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | NCT04108858 | Anatomic Stage ... HER2-Positive B... Metastatic Brea... | Copanlisib Pertuzumab Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | NCT04253262 | Metastatic Cast... | Rucaparib Copanlisib | 18 Years - | Brown University | |
| A Study of Copanlisib in Combination With Degarelix in People With Prostate Cancer | NCT06218667 | Prostate Cancer | Copanlisib Degarelix Radical Prostat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma | NCT04233697 | Lymphoma, T-Cel... | Copanlisib Romidepsin | 18 Years - | Columbia University | |
| Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | NCT03474744 | Marginal Zone L... | Copanlisib Rituximab | 18 Years - | University of Ulm | |
| Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma | NCT04431635 | Indolent Lympho... | Copanlisib Nivolumab Rituximab | 18 Years - | University of Michigan Rogel Cancer Center | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | NCT04156828 | Grade 3b Follic... Recurrent Diffu... Recurrent Folli... Refractory Diff... Non-Hodgkin's L... | Copanlisib Gemcitabine Carboplatin Dexamethasone Rituximab Pegfilgrastim | 18 Years - | University of Washington | |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | NCT05010096 | Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig... | Copanlisib Elimusertib | 18 Years - | M.D. Anderson Cancer Center | |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | NCT03789240 | Follicular Lymp... Non-Hodgkin's L... NHL | Rituximab Copanlisib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | NCT03884998 | Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom... | Copanlisib Nivolumab | 18 Years - | City of Hope Medical Center | |
| Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G) | NCT06360588 | Malignant Solid... | Biopsy Biospecimen Col... Copanlisib Radiologic Exam... | - | National Cancer Institute (NCI) | |
| Copanlisib and Avelumab as a Maintenance Therapy for Advanced Bladder Cancer | NCT05687721 | Advanced Urothe... | copanlisib Avelumab | 18 Years - | VA Office of Research and Development | |
| BAY1895344 and Copanlisib for the Treatment of Molecularly Selected Patients With Advanced Solid Tumors | NCT05010096 | Locally Advance... Metastatic Mali... Metastatic Mali... Recurrent Malig... | Copanlisib Elimusertib | 18 Years - | M.D. Anderson Cancer Center | |
| Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma | NCT03789240 | Follicular Lymp... Non-Hodgkin's L... NHL | Rituximab Copanlisib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer | NCT04108858 | Anatomic Stage ... HER2-Positive B... Metastatic Brea... | Copanlisib Pertuzumab Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | NCT04042051 | HER2-positive B... Metastatic Brea... Locally Advance... Unresectable Br... | Copanlisib Trastuzumab emt... | 18 Years - | Cancer Trials Ireland | |
| Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma | NCT03884998 | Chronic Lymphoc... Diffuse Large B... Follicular Lymp... Indolent Non-Ho... Lymphoplasmacyt... Marginal Zone L... Richter Syndrom... | Copanlisib Nivolumab | 18 Years - | City of Hope Medical Center | |
| Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | NCT03886649 | Non-Hodgkin Lym... | Copanlisib Venetoclax | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer | NCT03803761 | Anatomic Stage ... Metastatic Brea... Metastatic Mali... Prognostic Stag... | Copanlisib Fulvestrant | 18 Years - | National Cancer Institute (NCI) | |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) | NCT02465060 | Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ... | Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib | 18 Years - | National Cancer Institute (NCI) | |
| Copanlisib and Rituximab in Marginal Zone Lymphoma Patients | NCT03474744 | Marginal Zone L... | Copanlisib Rituximab | 18 Years - | University of Ulm | |
| Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma | NCT02631590 | Biliary Carcino... Gall Bladder Ca... Cholangiocarcin... Gastrointestina... | Cisplatin Gemcitabine Copanlisib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Study of Copanlisib and Ketogenic Diet | NCT04750941 | Follicular Lymp... Endometrial Can... | Copanlisib Ketogenic Diet | 18 Years - | Columbia University | |
| Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations | NCT05082025 | Endometrial Can... Ovarian Cancer | Copanlisib fulvestrant | 18 Years - | M.D. Anderson Cancer Center | |
| Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer | NCT02728258 | Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Metastatic Endo... Recurrent Uteri... | Copanlisib Laboratory Biom... | 18 Years - | NRG Oncology | |
| Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL | NCT04685915 | Chronic Lymphoc... | Ibrutinib Copanlisib Acalabrutinib | 18 Years - | Dana-Farber Cancer Institute | |
| Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma | NCT04156828 | Grade 3b Follic... Recurrent Diffu... Recurrent Folli... Refractory Diff... Non-Hodgkin's L... | Copanlisib Gemcitabine Carboplatin Dexamethasone Rituximab Pegfilgrastim | 18 Years - | University of Washington | |
| Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | NCT03711058 | Unresectable or... Colon Cancer | Copanlisib Nivolumab | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04155840 | Lymphoid Leukem... Non-Hodgkin's L... Chronic Lymphoc... Small Lymphocyt... | Copanlisib Rituximab Bendamustine | 65 Years - | University of Washington | |
| Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. | NCT03886649 | Non-Hodgkin Lym... | Copanlisib Venetoclax | 18 Years - | Swiss Group for Clinical Cancer Research | |
| Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT04155840 | Lymphoid Leukem... Non-Hodgkin's L... Chronic Lymphoc... Small Lymphocyt... | Copanlisib Rituximab Bendamustine | 65 Years - | University of Washington | |
| Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma | NCT02535247 | Lymphoma, T-Cel... | MK-3475 Copanlisib | 18 Years - | Fox Chase Cancer Center | |
| Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study) | NCT02705859 | HER2 Positive B... | Copanlisib Trastuzumab | 18 Years - | Cancer Trials Ireland |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
